The purpose of this study is to compare the pharmacokinetics and safety of NVP-1705 and NVP-1705-R.
Evaluate the pharmacokinetics and safety of NVP-1705 compared to NVP-1705-R
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
NVP-1705
NVP-1705-R
H Plus Yangji Hospital
Seoul, Nambusunhwan-ro, South Korea
Evaluation of Area under the plasma drug concentration-time curve(AUCt)
Pharmacokinetics parameter derived from plasma
Time frame: 0 ~ 48 hours
Evaluation of Maximum observed plasma concentration(Cmax)
Pharmacokinetics parameter derived from plasma
Time frame: 0 ~ 48 hours
Evaluation pf Area under the plasma drug concentration-time curve from time 0 to infinity(AUC∞)
Pharmacokinetics parameter derived from plasma
Time frame: 0 ~ 48 hours
Evaluation of AUCt/AUC∞
Pharmacokinetics parameter derived from plasma
Time frame: 0 ~ 48 hours
Evaluation of Time of peak concentration(Tmax)
Pharmacokinetics parameter derived from plasma
Time frame: 0 ~ 48 hours
Evaluation of Terminal phase of Half-life(t1/2)
Pharmacokinetics parameter derived from plasma
Time frame: 0 ~ 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.